drugset
Drugs / nab-rapamycin
last change Dec 2021 re-read 3 minutes ago

nab-rapamycin

targets MTOR via inhibition

Developed for
chordoma · classic Hodgkin lymphoma · colorectal cancer · desmoid tumor · epithelioid sarcoma · Ewing sarcoma · hepatocellular carcinoma · melanoma
+5 more · neoplasm with perivascular epithelioid cell differentiation · non-small cell lung carcinoma · renal cell carcinoma · squamous cell carcinoma · urothelial carcinoma
Investigated by
Aadi Bioscience, Inc. · Sarcoma Oncology Research Center, LLC

Trials 1

today NCT03190174 · Ph 1/2
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03190174 Aug 2017 → Dec 2021 Ewing sarcoma, chordoma, classic Hodgkin lymphoma, colorectal cancer +9 Sarcoma Oncology Research Center, LLC Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as nab-rapamycin ClinicalTrials.gov intervention name — accepted as the source's own label NCT03190174 ↗
Action Inhibit “mTOR inhibitor” NCT03190174 ↗
Target MTOR “the mammalian target of rapamycin (mTOR) inhibitor” NCT03190174 ↗